The Oct. 27 headline says J.P. Morgan upgraded Genmab, citing growth potential for its cancer drugs. But the supplied information doesn’t say what rating changed, why the firm made the move, or whether it set a new price target.
Genmab’s latest supplied close was US$44.67, and the stock was nearly flat that day.
Investor takeaway: The upgrade is the headline catalyst, but without the rating details, it’s hard to assess what J.P. Morgan’s move means.
Advertisement
Genmab AS
GMAB.US
GMAB.US
Genmab AS
WealthAwesomeMarket cap
$27.47B
P/E
35.2x
52W high
$45.45
52W low
$23.62
1W change
+14.33%
Beta
0.65
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Oct 27, 2026
Wall Street analysts forecast GMAB stock price to rise 8.1% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
C$48.27
+8.1% Upside
Previously C$45.95 on Oct 26, 2026
Current Price
C$44.67
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
46.2%
Annualized
90-Day Vol
36.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$53.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$47.41 | C$40.43 – C$55.60 |
| 60 trading days | C$50.32 | C$40.17 – C$63.03 |
| 90 trading days | C$53.40 | C$40.53 – C$70.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Genmab closed at US$44.67
That’s US$0.78 below the supplied 52-week high of US$45.45. The latest session saw 4,966 shares traded, far below the 20-day average of 5,174,824.
Bull case
The headline points to growth potential for Genmab’s cancer drugs. The stock is also up over the past week, month and year to date.
Bear case
The headline doesn’t include the new or previous rating or the analysis behind the upgrade. The stock was down 0.03% on the day, and the supplied facts don’t show that the upgrade drove earlier gains.
What happened: J.P. Morgan upgrade
The Oct. 27 end-of-day headline says J.P. Morgan upgraded Genmab based on the growth potential of its cancer drugs. The supplied facts don’t name the previous or new rating, identify a specific drug, explain the firm’s reasoning or provide a J.P. Morgan price target. The separate analyst target is an average across analysts, not a J.P. Morgan target. See Genmab’s GMAB.US profile.
Advertisement
What the numbers show: a nearly flat session
Genmab’s supplied closing price was US$44.67, down 0.03% for the day. The stock was up 14.33% over one week, 26.47% over one month and 40.38% year to date. Its close was near the top of the supplied 52-week range of US$23.62 to US$45.45.
The latest volume was 4,966 shares, or 0.95 times the stated 20-day average of 5,174,824 shares. These figures describe the stock’s performance but don’t show that the J.P. Morgan upgrade drove its earlier gains. The supplied average analyst target is US$48.27, but it isn’t attributed to J.P. Morgan. More details are on the analyst ratings page.
What to watch next: rating details
The supplied facts don’t include J.P. Morgan’s previous or new rating, the analysis behind the change or a firm-specific price target. Those details would help clarify what the upgrade means and which cancer-drug growth prospects the firm highlighted. The information provided also doesn’t establish a direct link between the upgrade and Genmab’s share-price moves.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
